Molecular Formula | C9H4N4O4 |
Molar Mass | 232.15 |
Density | 1.5507 (rough estimate) |
Melting Point | 300 °C |
Boling Point | 374.31°C (rough estimate) |
Solubility | H2O: 10mg/mL |
Appearance | solid |
Color | orange to red |
pKa | 8.16±0.20(Predicted) |
Storage Condition | protect from light |
Stability | Store Tightly Sealed at RT |
Refractive Index | 1.6590 (estimate) |
In vitro study | CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. |
In vivo study | CNQX (FG9065; 2-5 μM) reversibly blocks the Schaffer collateral and mossy fibre excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5 μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. Animal Model: Male Wistar rats weighing 180-200 g Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |
Hazard Symbols | Xi - Irritant |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. |
WGK Germany | 3 |
RTECS | VD1520000 |
HS Code | 29335990 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.308 ml | 21.538 ml | 43.076 ml |
5 mM | 0.862 ml | 4.308 ml | 8.615 ml |
10 mM | 0.431 ml | 2.154 ml | 4.308 ml |
5 mM | 0.086 ml | 0.431 ml | 0.862 ml |
biological activity | CNQX (FG9065) is an effective competitive AMPA/alginate receptor (AMPA/kainate receptor) antagonist, IC50 is 0.3 μM and 1.5 μM respectively. CNQX is a competitive non-NMDA receptor antagonist. CNQX blocks the expression of fear enhancement in rats. |
target | IC50: 0.3 μM (AMPA) and 1.5 μM (kainate receptor) |
in vitro research | CNQX (FG9065; 2-5μM) reversibly blocks the Schaffer collateral and mossy fiber excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5μM) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. |
in vivo research | CNQX (FG9065; 2-5μ M) reversibly blocks the Schaffer collateral and mossy fiber excitatory postsynaptic potential (EPSP), while sparing the fast and slow GABA-mediated inhibition in superfusion of hippocampal slices. CNQX (1-5μ M) produces a selective and dose-dependent reduction in the amplitude of the monosynaptic component of the DR-VRR recorded from lumbar spinal segments. Animal Model: Male Wistar weighing 180-200g Dosage: 0.75, 1.5, and 3 mg/kg Administration: IP; 20 min before testing Result: Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |
Animal Model: | Male Wistar rats weighing 180-200g |
Dosage: | 0.75, 1.5, and 3 mg/kg |
Administration: | IP; 20 min before testing |
Result: | Decreased the number of cocaine (IV; 0.25 mg/infusion) responses in a dose-dependent manner during the first 15-min cocaine-free interval |